194 related articles for article (PubMed ID: 38166741)
1. ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma.
Xing T; Li L; Rao X; Zhao J; Chen Y; Ju G; Xu Y; Gao X; Dong G; Xia X; Guan Y; Zhang L; Wen Z; Liang J
BMC Gastroenterol; 2024 Jan; 24(1):11. PubMed ID: 38166741
[TBL] [Abstract][Full Text] [Related]
2. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.
Sun R; Li J; Lin X; Yang Y; Liu B; Lan T; Xiao S; Deng A; Yin Z; Xu Y; Xiang Z; Wu B
Front Immunol; 2023; 14():1079495. PubMed ID: 37077908
[TBL] [Abstract][Full Text] [Related]
3. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
4. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
Li H; Wu K; Tao K; Chen L; Zheng Q; Lu X; Liu J; Shi L; Liu C; Wang G; Zou W
Hepatology; 2012 Oct; 56(4):1342-51. PubMed ID: 22505239
[TBL] [Abstract][Full Text] [Related]
5. TIGIT
Yu L; Liu X; Wang X; Yan F; Wang P; Jiang Y; Du J; Yang Z
Oncoimmunology; 2021; 10(1):1942673. PubMed ID: 34249476
[TBL] [Abstract][Full Text] [Related]
6. Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma.
Hong B; Qian Y; Zhang H; Sang YW; Cheng LF; Wang Q; Gao S; Zheng M; Yao HP
World J Gastroenterol; 2016 May; 22(18):4538-46. PubMed ID: 27182163
[TBL] [Abstract][Full Text] [Related]
7. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
Yen CS; Su ZR; Lee YP; Liu IT; Yen CJ
World J Gastroenterol; 2016 Jun; 22(22):5183-92. PubMed ID: 27298561
[TBL] [Abstract][Full Text] [Related]
8. Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis.
Chung YL; Wu ML
J Pathol; 2013 Aug; 230(4):377-87. PubMed ID: 23620081
[TBL] [Abstract][Full Text] [Related]
9. Combined identification of
Zhao Y; Yang B; Chen D; Zhou X; Wang M; Jiang J; Wei L; Chen Z
Aging (Albany NY); 2021 Feb; 13(3):4696-4712. PubMed ID: 33558447
[TBL] [Abstract][Full Text] [Related]
10. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival.
Qin SK; Li Q; Ming Xu J; Liang J; Cheng Y; Fan Y; Jiang J; Ye H; Tao H; Li L; Zheng L; Wei Z; Li S; Meng K; Ye B; Sun Y
Cancer Sci; 2020 Nov; 111(11):4218-4231. PubMed ID: 32889778
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B viral load affects prognosis of hepatocellular carcinoma.
Yu SJ; Kim YJ
World J Gastroenterol; 2014 Sep; 20(34):12039-44. PubMed ID: 25232241
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.
Li Z; Li N; Li F; Zhou Z; Sang J; Chen Y; Han Q; Lv Y; Liu Z
Medicine (Baltimore); 2016 Dec; 95(52):e5749. PubMed ID: 28033288
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma.
Li Z; Li N; Li F; Zhou Z; Sang J; Jin Z; Liu H; Han Q; Lv Y; Liu Z
Oncotarget; 2016 May; 7(18):26168-80. PubMed ID: 27034168
[TBL] [Abstract][Full Text] [Related]
14. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
[TBL] [Abstract][Full Text] [Related]
15. Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins.
Hayashi S; Nagaoka K; Tanaka Y
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681709
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
17. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B Virus Small Envelope Protein Promotes Hepatocellular Carcinoma Angiogenesis via Endoplasmic Reticulum Stress Signaling To Upregulate the Expression of Vascular Endothelial Growth Factor A.
Wu SX; Ye SS; Hong YX; Chen Y; Wang B; Lin XJ; Lin X
J Virol; 2022 Feb; 96(4):e0197521. PubMed ID: 34910612
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus P protein initiates glycolytic bypass in HBV-related hepatocellular carcinoma via a FOXO3/miRNA-30b-5p/MINPP1 axis.
Chen W; Jiang J; Gong L; Shu Z; Xiang D; Zhang X; Bi K; Diao H
J Exp Clin Cancer Res; 2021 Jan; 40(1):1. PubMed ID: 33390177
[TBL] [Abstract][Full Text] [Related]
20. The necroptosis related gene LGALS3 can be used as a biomarker for the adverse progression from chronic HBV infection to HCC.
Dong J; Zhang R; Xia Y; Jiang X; Zhou K; Li J; Guo M; Cao X; Zhang S
Front Immunol; 2023; 14():1142319. PubMed ID: 37180150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
